Skip to content

Medicenna Therapeutics Corp.

MDNAF

CIK 0001807983

← back to feed
Revenue (TTM)
—
FY Mar 2023
Net Income (TTM)
−10.05M
+55.5% YoY FY Mar 2023
EPS Diluted (TTM)
—
FY Mar 2023
Gross Margin
—
FY Mar 2023
Operating Margin
—
FY Mar 2023
Net Margin
—
FY Mar 2023
Free Cash Flow (TTM)
—
FY Mar 2023
Cash
33.6M
FY Mar 2023
Total Debt
—
FY Mar 2023
Shares Outstanding
69.64M sh
FY Mar 2023

Revenue & Net Income

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings